{"doi":"10.1016/j.ejca.2023.01.016","title":"Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation","abstract":null,"journal":"European Journal of Cancer","year":2023,"id":640693,"datarank":0.48283137373023016,"base_score":3.2188758248682006,"endowment":3.2188758248682006,"self_citation_contribution":0.48283137373023016,"citation_network_contribution":0.0,"self_endowment_contribution":0.48283137373023016,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":24,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1665217,"name":"Laetitia Da Meda","orcid":null,"position":1,"is_corresponding":false},{"id":1665220,"name":"Ines Pires da Silva","orcid":null,"position":2,"is_corresponding":false},{"id":133781,"name":"Wen Xu","orcid":null,"position":3,"is_corresponding":false},{"id":459668,"name":"Giovanni Grignani","orcid":"0000-0001-5515-569X","position":4,"is_corresponding":false},{"id":275801,"name":"Alexander M. Menzies","orcid":"0000-0001-5183-7562","position":5,"is_corresponding":false},{"id":68924,"name":"Matteo S. Carlino","orcid":"0000-0002-7861-4104","position":6,"is_corresponding":false},{"id":13750,"name":"Georgina V. Long","orcid":"0000-0001-8894-3545","position":7,"is_corresponding":false},{"id":275544,"name":"Serigne Lo","orcid":"0000-0001-5092-5544","position":8,"is_corresponding":false},{"id":1665229,"name":"Ina Nordman","orcid":null,"position":9,"is_corresponding":false},{"id":791025,"name":"Christopher Steer","orcid":"0000-0002-7677-3339","position":10,"is_corresponding":false},{"id":1665233,"name":"Megan Lyle","orcid":null,"position":11,"is_corresponding":false},{"id":1665234,"name":"Claudia Trojaniello","orcid":null,"position":12,"is_corresponding":false},{"id":68929,"name":"Paolo A. Ascierto","orcid":"0000-0002-8322-475X","position":13,"is_corresponding":false},{"id":1285231,"name":"Célèste Lebbé","orcid":"0000-0002-5854-7290","position":14,"is_corresponding":false},{"id":275800,"name":"Shahneen Sandhu","orcid":"0000-0002-8660-4475","position":15,"is_corresponding":false},{"id":1665214,"name":"Alison M. Weppler","orcid":"0000-0003-3769-490X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation","abstract":"<h4>Background</h4>Metastatic Merkel cell carcinoma (mMCC) is highly responsive to immune checkpoint inhibitors (ICIs); however, durability of response after treatment cessation and response to retreatment in the setting of progression is unknown.<h4>Methods</h4>Patients (pts) having mMCC from 10 centres who discontinued ICI treatment for a reason other than progression were studied.<h4>Results</h4>Forty patients were included. Median time on treatment was 13.5 months (range 1-35). Thirty-one patients (77.5%) stopped treatment electively while 9 patients (22.5%) stopped due to treatment-related toxicity. After median of 12.3 months from discontinuation, 14 pts (35%) have progressed (PD). Disease progression rate following ICI discontinuation was 26% (8 of 31) in patients who discontinued in complete response (CR), 57% (4 of 7) in patients in partial response and 100% (2 of 2) in those with stable disease. Median progression-free survival (PFS) after treatment cessation was 21 months (95% confidence interval [CI], 18- not reached [NR]), with a third of patients progressing during their first year off treatment. PFS was longer for patients who discontinued ICI electively (median PFS 29 months; 95% CI, 21-NR) compared to those who stopped due to toxicity (median PFS 11 months; 95% CI, 10-NR). ICI was restarted in 8 of 14 pts (57%) with PD, with response rate of 75% (4 CR, 2 partial response, 1 stable disease, 1 PD).<h4>Conclusion</h4>ICI responses in mMCC do not appear durable off treatment, including in patients who achieve a CR, though response to retreatment is promising. Extended duration of treatment needs to be investigated to optimise long-term outcomes.","is_dataset_classified":null,"base_score":3.2188758248682006,"endowment":3.2188758248682006,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36842413","pmcid":null,"openalex_id":"https://openalex.org/W4318465253","authors":[],"funders":[{"funder_name":"EMD Serono","grant_id":"","title":null},{"funder_name":"Bristol-Myers Squibb","grant_id":"","title":null},{"funder_name":"Bayer","grant_id":"","title":null},{"funder_name":"Roche","grant_id":"","title":null}],"total_grants":4,"fwci":2.7801,"citation_percentile":0.92128042,"influential_citations":0,"citation_trend":[{"year":2023,"count":8},{"year":2024,"count":7},{"year":2025,"count":6},{"year":2026,"count":3}],"oa_status":"closed","license":"https://doi.org/10.15223/policy-004","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0959804923000370?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0959804923000370?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.ejca.2023.01.016","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36842413","host_type":"repository"}],"fields_of_study":["Polyomavirus and related diseases","Multiple Sclerosis Research Studies","Bacteriophages and microbial interactions","Humans","Carcinoma, Merkel Cell","Immune Checkpoint Inhibitors","Progression-Free Survival","Skin Neoplasms","Withholding Treatment","Retrospective Studies"],"mesh_terms":["Progression-Free Survival","Immune Checkpoint Inhibitors","Humans","Retrospective Studies","Skin Neoplasms","Carcinoma, Merkel Cell","Withholding Treatment"],"keywords":["Medicine","Discontinuation","Internal medicine","Progressive disease","Gastroenterology","Progression-free survival","Surgery","Merkel cell carcinoma","Toxicity","Clinical endpoint","Oncology","Carcinoma","Chemotherapy","Randomized controlled trial","Retreatment","Treatment Cessation","Immune Checkpoint Inhibitors","Durability Of Response"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T13:16:19.065041Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}